(1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)propanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)propanol
• 英文别名: 3-[1-(4-Nitrophenyl)triazol-4-yl]propan-1-ol；3-[1-(4-nitrophenyl)triazol-4-yl]propan-1-ol
• 化学式: C₁₁H₁₂N₄O₃
• mdl: MFCD27019504
• 分子量: 248.241
• InChiKey: BZFXYIAOFSJDPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)propanol 在 potassium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 4-(3-(1-(4-nitrophenyl)-1H-1 ,2,3-triazol-4-yl)propyl)dimethylamine
  参考文献：
  名称：

  DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins

  摘要：

  The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people living with HIV. However, life-long treatments could result in the emergence of drug-resistant viruses that can progressively reduce the number of therapeutic options, facilitating the progression of the disease. In this scenario, we previously demonstrated that inhibitors of the human DDX3X helicase can represent an innovative approach for the simultaneous treatment of HIV and other viral infections such as Hepatitis c virus (HCV). We reported herein 6b, a novel DDX3X inhibitor that thanks to its distinct target of action is effective against HIV-1 strains resistant to currently approved drugs. Its improved in vitro ADME properties allowed us to perform preliminary in vivo studies in mice, which highlighted optimal biocompatibility and an improved bioavailability. These results represent a significant advancement in the development of DDX3X inhibitors as a novel class of broad spectrum and safe anti-HIV-1 drugs. (C) 2020 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112319
• 作为产物：
  描述：

  4-硝基苯胺 在 亚硝酸特丁酯 、 copper(ll) sulfate pentahydrate 、 L-ascorbic acid sodium salt 作用下， 以 水 、 乙腈 、 叔丁醇 为溶剂， 反应 0.34h， 生成 (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)propanol
  参考文献：
  名称：

  DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins

  摘要：

  The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people living with HIV. However, life-long treatments could result in the emergence of drug-resistant viruses that can progressively reduce the number of therapeutic options, facilitating the progression of the disease. In this scenario, we previously demonstrated that inhibitors of the human DDX3X helicase can represent an innovative approach for the simultaneous treatment of HIV and other viral infections such as Hepatitis c virus (HCV). We reported herein 6b, a novel DDX3X inhibitor that thanks to its distinct target of action is effective against HIV-1 strains resistant to currently approved drugs. Its improved in vitro ADME properties allowed us to perform preliminary in vivo studies in mice, which highlighted optimal biocompatibility and an improved bioavailability. These results represent a significant advancement in the development of DDX3X inhibitors as a novel class of broad spectrum and safe anti-HIV-1 drugs. (C) 2020 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112319

文献信息

• [EN] USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS<br/>[FR] UTILISATION D'INHIBITEURS DE DDX3 EN TANT QU'AGENTS ANTIPROLIFÉRATIFS
  申请人：AZIENDA OSPEDALIERA UNIV SENESE

  公开号：WO2017162834A1

  公开（公告）日：2017-09-28

  The present invention refers to compounds of formula I or II endowed with DDX3 inhibitory activity, relative pharmaceutical compositions and their use as antihyperproliferative agents. (I) or (II)

  这项发明涉及具有DDX3抑制活性的I或II式化合物，相关的药物组合物以及它们作为抗高增殖剂的用途。(I)或(II)
• [EN] HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS<br/>[FR] INHIBITEURS D'HÉLICASE DDX3 HUMAINE COMME AGENTS THÉRAPEUTIQUES
  申请人：AZIENDA OSPEDALIERA UNIV SENESE

  公开号：WO2016128541A1

  公开（公告）日：2016-08-18

  The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

  本发明涉及具有RNA解旋酶DDX3抑制活性的化合物I和II的公式及其治疗用途，特别是用于治疗病毒性疾病。
• HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS
  申请人：Azienda Ospedaliera Universitaria Senese

  公开号：EP3256461A1

  公开（公告）日：2017-12-20
• USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS
  申请人：Azienda Ospedaliera Universitaria Senese

  公开号：EP3432881A1

  公开（公告）日：2019-01-30
• DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins
  作者：Annalaura Brai、Valentina Riva、Francesco Saladini、Claudio Zamperini、Claudia Immacolata Trivisani、Anna Garbelli、Carla Pennisi、Alessia Giannini、Adele Boccuto、Francesca Bugli、Maurizio Martini、Maurizio Sanguinetti、Maurizio Zazzi、Elena Dreassi、Maurizio Botta、Giovanni Maga

  DOI：10.1016/j.ejmech.2020.112319

  日期：2020.8

  The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people living with HIV. However, life-long treatments could result in the emergence of drug-resistant viruses that can progressively reduce the number of therapeutic options, facilitating the progression of the disease. In this scenario, we previously demonstrated that inhibitors of the human DDX3X helicase can represent an innovative approach for the simultaneous treatment of HIV and other viral infections such as Hepatitis c virus (HCV). We reported herein 6b, a novel DDX3X inhibitor that thanks to its distinct target of action is effective against HIV-1 strains resistant to currently approved drugs. Its improved in vitro ADME properties allowed us to perform preliminary in vivo studies in mice, which highlighted optimal biocompatibility and an improved bioavailability. These results represent a significant advancement in the development of DDX3X inhibitors as a novel class of broad spectrum and safe anti-HIV-1 drugs. (C) 2020 The Authors. Published by Elsevier Masson SAS.